viewBlueJay Mining PLC

Bluejay Mining to continue working with Rio Tinto to evaluate potential of ore at Dundas

Rio Tinto is one of the world's major producers of ilmenite

Ilmenite from Greenland

Bluejay Mining PLC (LON:JAY) has reached agreement with Rio Tinto Iron and Titanium Canada for the further analysis of ore from the Dundas project in Greenland.

Rio Tinto and Bluejay are currently in talks about a commercial agreement relating to Dundas, although there is no guarantee at this stage that a deal will be done.

READ: BlueJay Mining upgrades resource for Dundas project as it presses ahead with PFS

Dundas has a  current JORC resource of 101mln tonnes at 7.1% of ilmenite, and has been confirmed as the highest-grade mineral sand ilmenite project globally.

Rio Tinto will analyse ilmenite from the Dundas project. This will include analysis of a smelter test sample at Rio’s Sorel-Tracy plant in Quebec, Canada.

"We are delighted to be working with Rio Tinto,” said Blujay chief executive Roderick McIllree.

“This summer one of the key-outcomes will be the delivery of a large bulk-sample to the Sorel-Tracy  plant.  We believe  that  the  ilmenite  from  Dundas  will  prove  to  be  a  very valuable material for the Sorel-Tracy plant operation and believe that the experience and expertise  from  Rio  Tinto  will  provide  an  opportunity  for  technological  and  economic optimization.”



Quick facts: BlueJay Mining PLC

Price: 7.4332 GBX

Market: AIM
Market Cap: £72.1 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Open Orphan's Cathal Friel hails £4mln contract with top-three global pharma...

Open Orphan PLC's (LON:ORPH) Cathal Friel tells Proactive its subsidiary hVIVO has signed a £4mln contract to conduct a human challenge study for an unnamed top-three global pharma company. The trial will take place at hVIVO’s London quarantine unit and is expected to be completed by the end of...

1 hour, 26 minutes ago

2 min read